CXCR3型
封锁
淋巴结
免疫学
医学
启动(农业)
T细胞
过继性细胞移植
癌症研究
淋巴
接种疫苗
癌症
免疫系统
联合疗法
细胞毒性T细胞
抗原
免疫疗法
癌基因
渗透(HVAC)
生物
细胞疗法
T淋巴细胞
癌症治疗
作者
Vinnycius Pereira Almeida,Lucy C. Garner,Sara Abdel Malak,Amanda Wicki,James McAuliffe,Laurine Noblecourt,Silvia Panetti,Emily E Steffke,Aneesha Bhandari,Lyn Yong,Ali Amini,Claire L. Hutchings,Francesco Andreata,Yuanqin Yang,Audrey Gérard,Matteo Iannacone,Ricardo A. Fernandes,Paul Klenerman,Benoît J. Van den Eynde,Carol Sze Ki Leung
出处
期刊:
[Cold Spring Harbor Laboratory]
日期:2026-10-11
标识
DOI:10.64898/2026.10.04.753375
摘要
Abstract Adoptive T-cell therapy (ACT) has demonstrated marked clinical benefit in hematological malignancies but has limited efficacy against solid tumors. Cancer vaccines can improve ACT, but the mechanisms underlying this combination are poorly understood. Here, we combined ACT with chimpanzee adenovirus ChAdOx1 (ChAd) and modified vaccinia Ankara (MVA) encoding tumor antigens. Whereas PD1 blockade failed to improve ACT, the combination with ChAd/MVA vaccination drove durable regression of established tumors, correlating with expansion of tumor-reactive T cells in lymphoid organs and increased tumor infiltration by T cells. Mechanistically, ChAd priming induced CXCR3 ligands (CXCL10 and CXCL9) in the vaccine-draining lymph node, thereby recruiting transferred T cells to this node independently of cognate antigen. CXCR3 expression on the transferred T cells, but not on host cells, was required for the anti-tumor effect of the combination therapy and favored T-cell accumulation in the vaccine-draining lymph node and the tumor. These findings identify CXCR3 on the transferred T cells as a determinant of ACT plus vaccination synergy and provide a rationale for combining viral-vector vaccines with TCR-T therapies, and for selecting or engineering T cells to retain CXCR3 expression. One Sentence Summary Viral vector vaccines synergize with TCR-T cell therapy to control solid tumors in a CXCR3-dependent manner.
科研通智能强力驱动
Strongly Powered by AbleSci AI